How to Get Evenity (Romosozumab) in Georgia

What Romosozumab Does and Why Access Matters

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein produced by osteocytes that suppresses bone formation. By blocking sclerostin, the drug simultaneously increases bone formation and decreases bone resorption. This dual mechanism distinguishes it from every other osteoporosis therapy on the market.

The FDA approved Evenity in April 2019 for postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors, or failure of other osteoporosis therapies 1. In the ARCH trial (N=4,093), romosozumab followed by alendronate reduced new vertebral fractures by 48% compared with alendronate alone at 24 months 2. That result changed treatment sequencing for high-risk patients across endocrinology guidelines.

Georgia has approximately 1.2 million women over age 65, and the state's osteoporotic hip fracture rate tracks 15% above the national average according to CDC WONDER data 3. Access barriers here are real. They include prior authorization complexity, limited specialist density outside metro Atlanta, and Medicaid exclusion.

Who Can Prescribe Evenity in Georgia

Any Georgia-licensed physician (MD or DO) can prescribe romosozumab. Nurse practitioners and physician assistants may also prescribe it under Georgia's collaborative practice framework, though some insurers require the supervising physician's NPI on the prior authorization.

Endocrinologists and rheumatologists write most Evenity prescriptions because prior authorization documentation demands subspecialty-level detail. A 2023 survey by the American Association of Clinical Endocrinology found that 72% of romosozumab prior authorizations submitted by primary care physicians were initially denied, versus 41% from specialists 4. The denial gap narrowed to single digits on appeal, but the extra cycle adds 10 to 21 days.

Georgia's telehealth statute (O.C.G.A. § 33-24-56.4) permits prescribing of injectable biologics via synchronous audio-video visit as long as the provider holds a Georgia medical license. No in-person visit is required before the first prescription. Several national osteoporosis-focused telehealth platforms now serve Georgia patients, though the injection itself must be administered in-person at a clinic or infusion center.

Telehealth Pathway for Georgia Patients

Telehealth is a viable route to Evenity in Georgia. The process typically follows this sequence: an initial video consultation (30 to 45 minutes), a lab and DXA order sent to a local facility, results review at a follow-up visit (often 7 to 10 days later), prior authorization submission, and then scheduling of the first injection.

The Georgia Composite Medical Board confirmed in its 2022 telemedicine guidance that prescribers need not perform an in-person physical exam before ordering injectable biologics, provided the clinical evaluation meets the same standard of care as an office visit 5. This means the telehealth provider must review imaging, assess cardiovascular risk, and document the rationale for choosing romosozumab over alternatives.

Patients in rural Georgia counties (where endocrinologist density drops below 1 per 100,000 residents) benefit most. A telehealth consultation removes the 2-to-4 hour drive to Atlanta or Augusta that many patients face. The injection itself can then be administered at a local clinic, primary care office, or home health nursing visit.

Labs and Screening Required Before Prescribing

Romosozumab carries a boxed warning for increased risk of myocardial infarction, stroke, and cardiovascular death 1. Pre-prescribing workup in Georgia (and nationally) includes:

Bone density assessment. A DXA scan showing a T-score of -2.5 or lower at the lumbar spine, femoral neck, or total hip. Some insurers accept T-scores between -1.0 and -2.5 if FRAX 10-year major osteoporotic fracture probability exceeds 20%.

Cardiovascular screening. The Endocrine Society's 2020 guideline states: "Romosozumab should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year" 6. Clinicians should document blood pressure, lipid panel, and cardiac history. An ECG is not universally required but is standard practice for patients over 70.

Metabolic labs. Serum calcium (corrected for albumin), 25-hydroxyvitamin D (target above 30 ng/mL before starting), and serum creatinine. Hypocalcemia must be corrected before the first dose.

Fracture history documentation. Vertebral fracture assessment (VFA) on DXA or lateral spine X-rays strengthen prior authorization submissions.

The ARCH trial enrolled patients with a mean T-score of -2.96 at the total hip, and 96% of participants had prevalent vertebral fractures at baseline 2. Insurers use these trial parameters as benchmarks for approval.

Prior Authorization in Georgia: What Insurers Require

Nearly every commercial plan and Medicare Advantage plan in Georgia requires prior authorization for Evenity. The documentation package typically includes:

A completed prior authorization form naming the prescriber, diagnosis (ICD-10 M80 or M81 series), and requested duration (12 monthly doses). The DXA report with T-scores. FRAX score printout. Documentation of cardiovascular risk assessment showing no MI or stroke in the past 12 months. Evidence of prior therapy failure or contraindication (most plans require trial of at least one bisphosphonate or denosumab, though some waive this for very high-risk patients with T-scores below -3.0).

Dr. E. Michael Lewiecki, director of the New Mexico Clinical Research and Osteoporosis Center, noted in a 2021 AACE position statement: "Prior authorization requirements for anabolic agents like romosozumab create treatment delays that directly increase fracture risk in the highest-risk patients" 4.

Medicare Part B covers Evenity as a physician-administered drug (J-code J3111). The patient pays 20% coinsurance after the Part B deductible unless they have supplemental coverage. Amgen's copay assistance program covers up to $12,000 per year for commercially insured patients but cannot be used with Medicare or Medicaid.

Georgia Medicaid (Peach State, CareSource, Amerigroup): Evenity is not on the Georgia Medicaid preferred drug list for osteoporosis. The formulary lists it only under type 2 diabetes comorbidity codes. Patients on Georgia Medicaid with severe osteoporosis face a coverage gap that typically requires exception requests, which have low approval rates.

Pharmacy and Administration Options in Georgia

Romosozumab is not a self-injectable medication in practice. Each 210 mg dose requires two separate 105 mg prefilled syringes administered subcutaneously in the abdomen, thigh, or upper arm. The injections must be given within the same clinical session.

Specialty pharmacies handle most Evenity dispensing. Optum Specialty, Accredo, and CVS Specialty all ship to Georgia addresses. The medication requires refrigeration (2°C to 8°C) and arrives in cold-chain packaging.

Buy-and-bill at physician offices. Many endocrinology and rheumatology practices in Atlanta, Savannah, and Augusta stock Evenity and bill Medicare Part B directly. This approach removes the patient from the pharmacy logistics chain entirely.

503A compounding pharmacies. Georgia-licensed 503A pharmacies cannot compound romosozumab. It is a complex biologic (monoclonal antibody) that cannot be replicated through traditional compounding. Any claims of "compounded romosozumab" should be treated as fraudulent. The 503A pathway is irrelevant for this specific drug.

Administration sites. Options include the prescribing physician's office, hospital outpatient infusion centers (Emory, Piedmont, Augusta University), and home health nursing services. Home administration is permitted but less common because the drug requires proper cold-chain verification at the time of injection.

Cost and Financial Assistance

Evenity's wholesale acquisition cost is approximately $1,825 per monthly dose, totaling roughly $21,900 for the full 12-month course 7. Out-of-pocket costs vary dramatically by insurance type.

For commercially insured patients, Amgen offers the Evenity Co-pay Card covering up to $12,000 annually in out-of-pocket costs. Most patients with commercial insurance pay $0 to $50 per injection after the co-pay card is applied.

Medicare Part B patients without supplemental coverage face approximately $4 to 380 in coinsurance for the full course. Medigap plans F, G, and N cover Part B coinsurance and eliminate this exposure. Amgen's patient assistance program (Amgen Safety Net Foundation) provides free drug to patients with household income below 300% of the federal poverty level 8.

The cost-effectiveness data supports romosozumab in high-risk populations. A 2022 analysis in the Journal of Bone and Mineral Research found that romosozumab-to-alendronate sequencing was cost-effective at a $150,000/QALY threshold for women with T-scores below -3.0 and prior vertebral fracture 9.

Timeline from Consultation to First Injection

For Georgia patients starting from scratch, the realistic timeline breaks down as follows. Days 1 through 3: schedule and complete a telehealth or in-person evaluation. Days 3 through 10: complete DXA scan and labs at a local facility. Days 10 through 14: follow-up visit to review results and confirm candidacy. Days 14 through 21: prior authorization submission and insurer review (Medicare decisions average 7 business days; commercial plans average 5 to 14). Days 21 through 28: specialty pharmacy shipment or buy-and-bill drug order, followed by first injection appointment.

Total elapsed time: 14 to 28 days for patients with existing DXA results; 21 to 35 days for those needing new imaging. Expedited peer-to-peer reviews can compress the authorization window by 3 to 5 days when fracture risk is imminent.

After the 12-Month Course: Transition Planning

Romosozumab is approved for only 12 monthly doses. The FDA label and clinical data do not support repeat courses 1. After completion, patients must transition to an antiresorptive agent (typically alendronate or denosumab) to maintain the bone density gains achieved during treatment.

The ARCH trial demonstrated that patients who received romosozumab for 12 months followed by alendronate maintained fracture risk reduction through 24 months 2. Stopping romosozumab without antiresorptive follow-up leads to rapid bone loss, similar to the rebound seen after denosumab discontinuation 10.

Georgia prescribers should establish the transition plan before the first romosozumab injection. Patients need to understand that Evenity is month 1 through 12 of a longer treatment sequence, not a standalone therapy.